ALK and non-small cell lung carcinoma: Therefore, EGFR activation retains the viability of ALK-TKI-treated cells in vivo, while EGFR inhibition improves the response of ALK-rearranged NSCLC tumors to lorlatinib treatment by preventing recurrence.